XOMA Royalty (XOMA) said Tuesday it has acquired a 50% economic interest in all future milestones and royalties associated with more than 60 early-stage programs under Twist Bioscience's (TWST) biopharma business for an upfront payment of $15 million.

The deal brings XOMA's portfolio to over 100 assets ranging from commercial therapeutics to pre-clinical programs, the company said.